SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brad C. Dunlap who wrote (299)1/21/1997 11:26:00 PM
From: Webhead   of 1762
 
I found this interesting statement buried in the Genentech 4th Quarter statement:

-- Genentech's development partner, IDEC Pharmaceuticals,
completed Phase III clinical trials of the IDEC-C2B8 antibody for the
treatment of non-Hodgkin's B-cell lymphoma -- which confirmed the
safety and efficacy seen in Phase II trials -- and began preparing to
submit regulatory filings in the first quarter of 1997.

I would interpret this to mean that IDEC will petition the FDA to review IDEC-C2B8 within the next 3 months. Hopefully, this will really get the ball rolling!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News